{"id":"https://openalex.org/W2746867800","doi":null,"title":"New Therapeutic Strategies for Triple-Negative Breast Cancer.","display_name":"New Therapeutic Strategies for Triple-Negative Breast Cancer.","alternate_titles":[],"publication_year":2017,"publication_date":"2017-02-15","ids":{"openalex":"https://openalex.org/W2746867800","mag":"2746867800","pmid":"https://pubmed.ncbi.nlm.nih.gov/28205193"},"language":"en","primary_location":{"id":"pmid:28205193","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28205193","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology (Williston Park, N.Y.)","raw_type":"Journal Article"},"parent_works":[],"lineage":["https://openalex.org/W2746867800"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5007230958","display_name":"Borb\u00e1la Sz\u00e9kely","orcid":"https://orcid.org/0000-0002-0387-7516","observed_orcids":["https://orcid.org/0000-0002-0387-7516"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Borb\u00e1la Sz\u00e9kely","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039412967","display_name":"Andrea L.M. Silber","orcid":"https://orcid.org/0000-0002-3339-6959","observed_orcids":["https://orcid.org/0000-0002-3339-6959"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Andrea L M Silber","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5021113979","display_name":"Lajos Pusztai","orcid":"https://orcid.org/0000-0001-9632-6686","observed_orcids":["https://orcid.org/0000-0001-9632-6686"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Lajos Pusztai","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":4.0772,"has_fulltext":false,"cited_by_count":79,"citation_normalized_percentile":{"value":0.95974063,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":100},"biblio":{"volume":"31","issue":"2","first_page":"130","last_page":"137"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":1.0},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.859000027179718},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9670000076293945},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9769999980926514},{"id":"https://openalex.org/keywords/platinum-based-drugs","display_name":"platinum drugs","score":0.6700000166893005},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.9829999804496765},{"id":"https://openalex.org/keywords/adjuvant-therapy","display_name":"adjuvant therapy","score":0.8840000033378601},{"id":"https://openalex.org/keywords/genomic-heterogeneity","display_name":"genomic heterogeneity","score":0.703000009059906},{"id":"https://openalex.org/keywords/tp53","display_name":"TP53","score":0.7910000085830688},{"id":"https://openalex.org/keywords/taxanes","display_name":"taxanes","score":0.7110000252723694},{"id":"https://openalex.org/keywords/capecitabine","display_name":"capecitabine","score":0.8640000224113464},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.6539999842643738}],"concepts":[{"id":"https://openalex.org/C2780110267","wikidata":"https://www.wikidata.org/wiki/Q7843332","display_name":"Triple-negative breast cancer","level":4,"score":0.706246018409729},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6731730103492737},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6456764340400696},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6381282210350037},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.6318286061286926},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5120061039924622},{"id":"https://openalex.org/C2780194787","wikidata":"https://www.wikidata.org/wiki/Q4836333","display_name":"BRCA mutation","level":4,"score":0.456326961517334},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4529517889022827},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4396813213825226},{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.4272298514842987},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.41900867223739624},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3357408046722412},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2648254334926605},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.17258086800575256},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.14980468153953552},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.102569580078125},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.07067161798477173},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000067856","descriptor_name":"Poly(ADP-ribose) Polymerase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D020360","descriptor_name":"Neoadjuvant Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D056572","descriptor_name":"Histone Deacetylase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D064726","descriptor_name":"Triple Negative Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:28205193","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28205193","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology (Williston Park, N.Y.)","raw_type":"Journal Article"},{"id":"mag:2746867800","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28205193","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3006563254","https://openalex.org/W2399127659","https://openalex.org/W4210858119","https://openalex.org/W2346842804","https://openalex.org/W2147902297","https://openalex.org/W4293029435","https://openalex.org/W2107816412","https://openalex.org/W2109270475","https://openalex.org/W7150229900","https://openalex.org/W2808672171"],"abstract_inverted_index":{"Relatively":[0],"few":[1],"clinically":[2],"important":[3,39,82,184],"therapeutic":[4],"advances":[5],"have":[6,175],"occurred":[7],"in":[8,72,84,180],"the":[9,17,73,88,110,120,134],"treatment":[10,74],"of":[11,19,37,63,75,112,136,146],"triple-negative":[12],"breast":[13],"cancer":[14,93,140],"(TNBC)":[15],"since":[16],"introduction":[18],"taxanes":[20],"as":[21,47],"adjuvant":[22,115],"therapy":[23],"over":[24],"20":[25],"years":[26],"ago.":[27],"However,":[28],"this":[29,167],"is":[30],"rapidly":[31],"changing":[32],"due":[33],"to":[34,109,132],"a":[35,129],"variety":[36],"conceptually":[38],"clinical":[40],"trials":[41,116,186],"and":[42,51,61,125,153],"emerging":[43],"new":[44],"options":[45],"such":[46],"immune":[48],"checkpoint":[49],"inhibitors":[50,62],"antibody-drug":[52],"conjugates.":[53],"Evidence":[54],"also":[55],"increasingly":[56],"supports":[57],"that":[58,90,127],"platinum":[59,123],"drugs":[60,124],"poly":[64],"(ADP-ribose)":[65],"polymerase,":[66],"or":[67],"PARP,":[68],"are":[69,187],"particularly":[70],"effective":[71],"germline":[76],"BRCA-mutant":[77],"cancers,":[78],"including":[79],"TNBC.":[80],"An":[81],"development":[83],"early-stage":[85],"TNBC":[86,147],"was":[87],"recognition":[89],"extensive":[91],"residual":[92,139],"after":[94,141],"neoadjuvant":[95,142],"chemotherapy":[96],"identifies":[97],"patients":[98,137],"who":[99],"remain":[100],"at":[101],"high":[102],"risk":[103],"for":[104],"recurrence.":[105],"This":[106],"has":[107,148],"led":[108],"design":[111],"two":[113],"ongoing":[114],"(one":[117],"testing":[118],"pembrolizumab,":[119],"other":[121,162],"investigating":[122],"capecitabine)":[126],"offer":[128],"\"second":[130],"chance\"":[131],"improve":[133],"survival":[135],"with":[138,166],"chemotherapy.":[143],"Genomic":[144],"analysis":[145],"revealed":[149],"large-scale":[150],"transcriptional,":[151],"mutational,":[152],"copy":[154],"number":[155],"heterogeneity,":[156,169],"without":[157],"any":[158],"frequently":[159],"recurrent":[160],"mutations,":[161],"than":[163],"TP53.":[164],"Consistent":[165],"molecular":[168],"most":[170],"targeted":[171],"agents,":[172],"so":[173],"far,":[174],"demonstrated":[176],"low":[177],"overall":[178],"activity":[179],"unselected":[181],"TNBC,":[182],"but":[183],"\"basket\"":[185],"ongoing.":[188]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2746867800","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":15},{"year":2020,"cited_by_count":9},{"year":2019,"cited_by_count":9},{"year":2018,"cited_by_count":19},{"year":2017,"cited_by_count":11}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2017-08-31T00:00:00"}
